Press Release - 2026-08-25
Celea Therapeutics – Deupirfenidone (LYT-100)
Other
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
Press Release - 2026-07-13
Celea Therapeutics – Deupirfenidone (LYT-100)
Other
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Press Release - 2026-07-02
Celea Therapeutics – Deupirfenidone (LYT-100)
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
